Herpes Labialis (Oral Herpes) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) – Pipeline Review, H2 2016’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)

The report reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Herpes Labialis (Oral Herpes) therapeutics and enlists all their major and minor projects

The report assesses Herpes Labialis (Oral Herpes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AiCuris GmbH and Co KG

Beech Tree Labs, Inc.

Foamix Pharmaceuticals Ltd.

Mymetics Corporation

NanoViricides, Inc.

Onxeo SA

Shulov Innovative Science Ltd.

TGV-Laboratories

Vironova AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Herpes Labialis (Oral Herpes) Overview 7

Therapeutics Development 8

Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 8

Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 9

Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 10

Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes 11

Herpes Labialis (Oral Herpes) - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Herpes Labialis (Oral Herpes) - Products under Development by Companies 15

Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes 16

Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 17

AiCuris GmbH and Co KG 17

Beech Tree Labs, Inc. 18

Foamix Pharmaceuticals Ltd. 19

Mymetics Corporation 20

NanoViricides, Inc. 21

Onxeo SA 22

Shulov Innovative Science Ltd. 23

TGV-Laboratories 24

Vironova AB 25

Herpes Labialis (Oral Herpes) - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

acyclovir - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

acyclovir - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Aspidasept - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

B-220 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BTL-TMLHSV - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

herpes simplex virus [type 1, 2] (virus like particle) vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

herpes simplex virus [type 1, 2] vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

pritelivir - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule for Cold Sores - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Teg-379 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ZEP-3 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Herpes Labialis (Oral Herpes) - Dormant Projects 49

Herpes Labialis (Oral Herpes) - Discontinued Products 50

Herpes Labialis (Oral Herpes) - Product Development Milestones 51

Featured News & Press Releases 51

Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada 51

Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 51

Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 52

May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 52

Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 53

Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 54

Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 54

May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 55

Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 55

Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 56

Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 56

Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress 57

Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial 57

Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad 58

Aug 26, 2010: BioAlliance Pharma Plans To Submit Acyclovir Lauriad NDA 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2016 8

Number of Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Herpes Labialis (Oral Herpes) – Pipeline by AiCuris GmbH and Co KG, H2 2016 17

Herpes Labialis (Oral Herpes) – Pipeline by Beech Tree Labs, Inc., H2 2016 18

Herpes Labialis (Oral Herpes) – Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19

Herpes Labialis (Oral Herpes) – Pipeline by Mymetics Corporation, H2 2016 20

Herpes Labialis (Oral Herpes) – Pipeline by NanoViricides, Inc., H2 2016 21

Herpes Labialis (Oral Herpes) – Pipeline by Onxeo SA, H2 2016 22

Herpes Labialis (Oral Herpes) – Pipeline by Shulov Innovative Science Ltd., H2 2016 23

Herpes Labialis (Oral Herpes) – Pipeline by TGV-Laboratories, H2 2016 24

Herpes Labialis (Oral Herpes) – Pipeline by Vironova AB, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Herpes Labialis (Oral Herpes) – Dormant Projects, H2 2016 49

Herpes Labialis (Oral Herpes) – Discontinued Products, H2 2016 50

List of Figures

List of Figures

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2016 8

Number of Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Targets, H2 2016 27

Number of Products by Stage and Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Top 10 Molecule Types, H2 2016 33

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports